Recently, a study sought to determine whether dose reductions of anti–tumor necrosis factor (anti-TNF) therapies are possible for long-term treatment of spondyloarthritis, and found that a reduced dose is noninferior to a full dose in patients in sustained clinical remission.
Anti—tumor necrosis factor (anti-TNF) therapies are often efficacious in treating spondyloarthritis, but the optimal duration and dose for long-term treatment are not yet clear; currently, doses recommended for acute and chronic disease are the same. In addition to the high cost of these drugs and their potential to increase the risk of serious infections, it is not yet known whether chronic use may increase malignancies or demyelinating diseases. Recently, a study sought to determine whether dose reductions are possible for long-term treatment of spondyloarthritis, and found that a reduced dose is noninferior to a full dose in patients in sustained clinical remission.
The prospective, multicenter, randomized open-label trial was conducted at 22 studies in Spain. Patients were eligible to enroll if they were taking the recommended dose of infliximab, adalimumab, etanercept, or golimumab and had been in clinical remission for 6 months or more.
The 126 enrolled patients were randomized to receive either the full recommended dose of their anti-TNF agent (n = 63) or a reduced dose (n = 63), according to an agreed-upon protocol. For example, in those taking adalimumab, patients with standard dosing received 40 mg every 2 weeks, while the reduced dose group received 40 mg every 3 weeks. In those taking infliximab, the full-dose group received 5 mg per kg every 6 to 8 weeks, while the reduced-dose group received 3 mg per kg every 8 weeks. The primary end point was the proportion of patients with low disease activity (LDA) at 1 year.
The study found that the proportion of patients with LDA at 1 year was 83.9% (95% CI, 64.8%-102.7%) in the full-dose arm and 81.3% (95% CI, 62.8%-99.8%) in the reduced-dose arm. The absolute difference in LDA at 1 year in the per-protocol set population was —2.5% (95% CI, –16.6 to 11.7%). The lower bound for the CI in the control arm was greater than 60%, fulfilling prespecified validation criteria.
The percentage of patients in clinical remission, a key secondary end point, at 1 year was 83.7% (95% CI, 64.7%-102.7%) in the full-dose arm and 78.2% (95% CI, 59.7%-96.8%) in the reduced-dose arm, with absolute differences between treatment groups of −5.5% (95% CI, −20.6% to 9.7%) (P = .480)
Serious treatment-related adverse events or infections were reported in 11.3% of the full-dose group, and in 3.3% of the reduced-dose group (P = .164). Treatment was discontinued by 9.7% of the full-dose group and 21.3% of the reduced-dose group (P = .086).
“This trial has shown that a dose-reduction strategy may be non-inferior to full-dose treatment in patients with AS in persistent clinical remission with [anti-TNF agents], in terms of maintenance of LDA after 1 year,” write the investigators.
Reference
Gratacós J, Pontes C, Juanola X, et al. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondylarthrosis. Arthritis Res Ther. 2019;21(1):11. doi: 10.1186/s13075-018-1772-z.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.